Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Primary Aldosteronism
Clinical Journal of the American Society of Nephrology · 2026-10 · 21 (10) · 1772-1782
DOI: 10.2215/cjn.0000001144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 28.07.2026. Verfasst von Li-Yang Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Hyperaldosteronism, Mineralocorticoid Receptor Antagonists. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Science and Technology Council, National Taiwan University Hospital, Ministry of Health and Welfare.
Abstract (Originalsprache)
Key Points Primary aldosteronism patients on mineralocorticoid receptor antagonists face high cardio-renal risks, but evidence for effective add-on therapies remains limited. Adding sodium-glucose cotransporter 2 inhibitors to mineralocorticoid receptor antagonists reduced 3-year mortality by 6.6%, major adverse cardiovascular events by 2.7%, and major adverse kidney events by 9.7% absolute risk. Mineralocorticoid receptor antagonist-sodium-glucose cotransporter 2 inhibitor combination therapy offers a promising strategy to improve long-term survival and organ preservation in primary aldosteronism.
Background
Patients with primary aldosteronism (PA) are at an increased risk of cardiovascular and kidney complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated protective effects in individuals at a high risk of cardiorenal events. This study investigates whether adding SGLT2is to mineralocorticoid receptor antagonists (MRAs) associates with better outcomes in patients with PA.
Methods
We retrospectively analyzed TriNetX data (February 1, 2014 to February 1, 2025) using an incident cohort design in adults with PA treated with MRAs within 3 months before or after PA diagnosis, excluding those who underwent adrenalectomy. Patients were divided into two cohorts based on initiation of an SGLT2i within 3 months of the PA diagnosis. The primary outcome was 3-year all-cause mortality; secondary outcomes included major adverse cardiovascular events and major adverse kidney events. We performed 1:1 propensity score matching and estimated adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) using Cox proportional hazards models.
Results
A total of 24,074 patients with PA were included; 34% had comorbid diabetes, 26% had heart failure, and 2524 (11%) received SGLT2is. After a well-balanced propensity score matching, 2507 SGLT2i users were compared with 2507 nonusers. In the matched cohort, the incidence of all-cause mortality was 12% in SGLT2i users and 18% in nonusers. The combination of SGLT2i with MRA was associated with a lower risk of all-cause mortality (aHR, 0.59; 95% CI, 0.51 to 0.68; absolute risk reduction [ARR], 7%), major adverse cardiovascular event (aHR, 0.81; 95% CI, 0.69 to 0.94; ARR, 3%), and major adverse kidney event (aHR, 0.58; 95% CI, 0.52 to 0.65; ARR, 10%). Kaplan–Meier survival curves for all outcomes demonstrated early divergence and remained distinct through the 3-year follow-up period.
Conclusions
In patients with PA, adding SGLT2is to MRAs is associated with lower mortality and cardiorenal complications. These associations offer a rationale for evaluation of this combined strategy to improve long-term outcomes in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Tainan Municipal Hospital, Tainan, Taiwan.
- Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Foundation, Taiwan.
- School of Medicine, Tzu Chi University, Hualien, Taiwan.
- Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
ORCID-Profile: Li-Yang Chang, Chieh Huang, Ching-Chun Su, Cheng-Hsuan Tsai, Che-Hsiung Wu, Chun-Fu Lai, Vin-Cent Wu
Förderung
- National Science and Technology Council
- National Taiwan University Hospital
- Ministry of Health and Welfare
- Mrs. Hsiu-Chin Lee Kidney Research Foundation
Zitieren
APA
Chang, L. Y., Huang, C., Su, C. C., Tsai, C. H., Wu, C. H., Lai, C. F., Wu, V. C., & Taiwan Primary Aldosteronism Investigation (TAIPAI) study group (2026). Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Primary Aldosteronism. Clinical Journal of the American Society of Nephrology, 21(10), 1772-1782. https://doi.org/10.2215/cjn.0000001144
Vancouver
Chang LY, Huang C, Su CC, Tsai CH, Wu CH, Lai CF, et al. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Primary Aldosteronism. Clinical Journal of the American Society of Nephrology. 2026;21(10):1772-1782. doi:10.2215/cjn.0000001144
BibTeX
@article{Chang2026,
author = {Chang, Li-Yang and Huang, Chieh and Su, Ching-Chun and Tsai, Cheng-Hsuan and Wu, Che-Hsiung and Lai, Chun-Fu and Wu, Vin-Cent and Taiwan Primary Aldosteronism Investigation (TAIPAI) study group, Taiwan Primary Aldosteronism Investigation (TAIPAI) study group},
title = {Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Primary Aldosteronism},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
volume = {21},
number = {10},
pages = {1772--1782},
doi = {10.2215/cjn.0000001144}
}
EUVIMED